Key terms
About GSK
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GSK news
Yesterday
11:57am ET
GSK Executives Reinvest Dividends in Shares
Yesterday
10:40am ET
Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)
Yesterday
7:00am ET
GSK’s Shingrix Vaccine Proves Long-term Efficacy
Yesterday
7:00am ET
GSK’s New Antibiotic Shows High Success Rate
Apr 16
10:27am ET
GSK Corrects Executive Shareholding Disclosure
Apr 16
6:57am ET
GSK’s 5-in-1 Meningococcal Vaccine Under FDA Review
Apr 16
6:21am ET
GSK meningococcal ABCWY vaccine candidate accepted for FDA review
Apr 15
9:04pm ET
GSK Executives Invest in Company’s Future
Apr 08
3:14pm ET
GSK price target raised to 1,725 GBp from 1,575 GBp at Barclays
Apr 08
8:13am ET
ViiV Healthcare announces FDA approval of Dovato for adolescents with HIV
Apr 04
7:23am ET
CureVac announces Phase 2 interim data from influenza vaccine program
Apr 02
1:59pm ET
GSK Updates Total Voting Rights for Shareholders
Mar 26
8:57am ET
GSK Executive Sells Shares on LSE
Mar 22
1:57pm ET
GlaxoSmithKline Executes Major Share Transfer
Mar 20
5:14pm ET
GSK caps U.S. out-of-pocket costs at $35/month for portfolio of COPD inhalers
Mar 19
2:35pm ET
GSK price target raised to 2,040 GBp from 1,860 GBp at UBS
Mar 18
11:11am ET
Pfizer (NYSE:PFE) to Offload Haleon (NYSE:HLN) Shares Worth $2.5B
Mar 18
10:27am ET
GSK’s Jemperli Shows Promise in Endometrial Cancer Trial
Mar 18
9:38am ET
GSK reports ‘clinically meaningful’ overall survival results from RUBY trial
Mar 18
8:35am ET
5 Stocks that Analysts Love in March 2024
Mar 13
11:00am ET
European Stocks: Unnoticed Records, Overlooked Opportunities
Mar 07
6:08am ET
GSK announces positive results from DREAMM-8 phase 3 trial for Blenrep
Mar 06
12:11pm ET
ViiV Healthcare announces interim data of LATITUDE phase III trial
Mar 06
11:10am ET
ViiV Healthcare says interim data show superior efficacy of long-acting Cabenuva
Mar 04
2:50pm ET
GSK price target raised to 1,830 GBp from 1,730 GBp at Morgan Stanley
Mar 04
1:44pm ET
GSK says study shows cabotegravir can be dosed at four months
Mar 04
4:58am ET
GSK upgraded to Buy from Neutral at Guggenheim
Feb 29
6:10am ET
GSK confirms confidential settlement reached with Boyd/Steenvoord over Zantac
Feb 26
6:59am ET
GSK announces EAGLE-1 phase III trial met primary efficacy endpoint
Feb 21
6:13am ET
GSK announces LATITUDE phase III interim trial demonstrates ‘superior efficacy’
Feb 15
1:05pm ET
GSK price target raised to 1,820 GBp from 1,650 GBp at Berenberg
No recent press releases are available for GSK
GSK Financials
Key terms
Ad Feedback
GSK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GSK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range